These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 24132613

  • 1. Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin.
    Mezquita Raya P, Pérez A, Ramírez de Arellano A, Briones T, Hunt B, Valentine WJ.
    Diabetes Ther; 2013 Dec; 4(2):417-30. PubMed ID: 24132613
    [Abstract] [Full Text] [Related]

  • 2. Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin.
    Pérez A, Mezquita Raya P, Ramírez de Arellano A, Briones T, Hunt B, Valentine WJ.
    Diabetes Ther; 2015 Mar; 6(1):61-74. PubMed ID: 25742705
    [Abstract] [Full Text] [Related]

  • 3. The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.
    Franch-Nadal J, Malkin SJP, Hunt B, Martín V, Gallego Estébanez M, Vidal J.
    Adv Ther; 2022 Jul; 39(7):3180-3198. PubMed ID: 35553372
    [Abstract] [Full Text] [Related]

  • 4. Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
    Hunt B, Kragh N, McConnachie CC, Valentine WJ, Rossi MC, Montagnoli R.
    Clin Ther; 2017 Jul; 39(7):1347-1359. PubMed ID: 28625506
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.
    Barnett AH, Arnoldini S, Hunt B, Subramanian G, Hoxer CS.
    Diabetes Obes Metab; 2018 Aug; 20(8):1921-1927. PubMed ID: 29652101
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme.
    Bain SC, Hansen BB, Malkin SJP, Nuhoho S, Valentine WJ, Chubb B, Hunt B, Capehorn M.
    Diabetes Ther; 2020 Jan; 11(1):259-277. PubMed ID: 31833042
    [Abstract] [Full Text] [Related]

  • 11. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
    Lee WC, Samyshkin Y, Langer J, Palmer JL.
    J Med Econ; 2012 Jan; 15 Suppl 2():28-37. PubMed ID: 22834986
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
    Gao L, Zhao FL, Li SC.
    Int J Technol Assess Health Care; 2012 Oct; 28(4):436-44. PubMed ID: 23006540
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
    Johansen P, Chubb B, Hunt B, Malkin SJP, Sandberg A, Capehorn M.
    Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia.
    Malkin SJP, Russel-Szymczyk M, Liidemann G, Volke V, Hunt B.
    Diabetes Ther; 2019 Feb; 10(1):159-176. PubMed ID: 30535837
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.